ICML 2025 | The outcomes of autoSCT and alloSCT in R/R Burkitt lymphoma: an analysis of EBMT Registry data

Yeah, that was an interesting analysis in the lymphoma working party of the EBMT and data on Burkitt lymphoma are quite rare as well. So relapsed/refractory Burkitt lymphoma has a very poor outcome and often these patients, we don’t reach a second remission that we can go into transplant and there are not many trials ongoing, either on first line or second line with new substances, which is very sad. So, the registry is a good chance to get more information and we performed an analysis on 1200 patients, approximately 950 with autologous and 250 with allogeneic transplantation. And we saw that in first and in second remission autologous transplantation is superior to allogeneic transplantation in terms of overall survival with a very significant difference. Also non-relapse mortality for sure, which is significantly higher in allogeneic transplantation. We verified this by propensity score analysis and was a little bit surprising because we didn’t expect that autologous transplantation and high dose chemotherapy is superior to allogeneic transplantation. So we hope that new trials for relapsed/refractory Burkitt lymphoma will start so that we have a better chance to bring these patients into second remission and then do a consolidative autologous transplantation. However, this analysis has some limitations it’s a retrospective analysis and some baseline data were missing but that’s the nature of retrospective analysis and registry analysis and with the 1200 patients we think it’s it provides some additional data and basis that we rather recommend autologous transplantation than allogeneic if a good stem cell product is available.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.